

K061511

K

JUL 10 2006

**510(k) Special Summary**  
**R&D Systems, Inc. CBC-3D + CRP Hematology Control**

Date of Summary:	May 30, 2006
Company Name:	R&D Systems, Inc. 614 McKinley Place N.E. Minneapolis, MN 55413
Contact name:	Ralph E. Hogancamp 612-656-4413, FAX 612-379-6580
Classification name:	Hematology Quality Control Mixture
Product name:	R&D CBC-3D + CRP Hematology Control
CFR section:	864.8625 Hematology quality control mixture.
Device Class:	Class II

**Predicate Device:** R&D Systems CBC-3D Hematology Control, K843962 manufactured by R&D Systems, Inc. 614 McKinley Place N.E., Minneapolis, MN 55413

**Description:** This control is a tri-level control to monitor values on automated and semi-automated impedance type hematology analyzers. It can also be used for manual methods.

**Intended use:** R&D CBC-3D + CRP Hematology Control is a tri-level control to monitor values on automated and semi-automated impedance type hematology analyzers. It can also be used for manual methods. Refer to assay sheet for specific instrument models.

**Comparison:** Both products are used to monitor automated and semi-automated impedance type hematology instruments. The R&D CBC-3D + CRP added a new parameter.

**Discussion:** Laboratory testing of 3 validation lots has shown R&D CBC-3D + CRP Hematology Control to have substantial equivalence in performance, precision and stability to the predicate device. R&D CBC-3D + CRP Hematology Control passed the acceptance criteria of remaining within the assay range over the life of the product. R&D CBC-3D + CRP Hematology Control has demonstrated precision as indicated by the small standard deviation and % CV's obtained during laboratory testing. Expiration dating has been established at 105 days (closed vial) and 14 days (open vial) when stored at 2 - 8° C and handled according to instructions for use.

**Conclusion:** R&D CBC-3D + CRP Hematology Control is a safe and effective control for the above intended use when used as instructed in the package insert.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Mr. Ralph E. Hogancamp  
Regulatory Affairs  
R&D Systems, Inc.  
614 McKinley Place N.E.  
Minneapolis, Minnesota 55413

**JUL 10 2006**

Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

Re: k061511  
Trade/Device Name: R&D LH-nRBC Hematology Control  
Regulation Number: 21 CFR § 864.8625  
Regulation Name: Hematology Quality Control Mixture  
Regulatory Class: II  
Product Code: JPK  
Dated: June 28, 2006  
Received: June 29, 2006

Dear Mr. Hogancamp:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

Page 2 --

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>

Sincerely yours,

A handwritten signature in black ink, reading "Robert L. Becker, Jr." with a stylized flourish at the end.

Robert L. Becker, Jr., MD, Ph.D

Director

Division of Immunology and Hematology

Office of *In Vitro* Diagnostic Device

Evaluation and Safety

Center for Devices and

Radiological Health

Enclosure

**Indications for Use**

**510(k) Number (if known):** K 061511

**Device Name:** R&D LH-nRBC Hematology Control


**Indications for Use:**

R&D CBC-3D + CRP Hematology Control is a tri-level control designed to monitor values on automated and semi-automated impedance type hematology analyzers. Refer to assay sheet for specific instrument models.

Prescription Use X AND/OR Over-The-Counter Use \_\_\_\_\_  
(Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE TO  
USE ANOTHER PAGE IF NEEDED)

---

  
Division Sign Off

Office of In Vitro Diagnostic Device  
Evaluation and Safety

Page 1 of 1

K061511